{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:05:50Z","timestamp":1791547550097,"version":"4.3.4"},"reference-count":34,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>\n                      Survodutide is an investigational glucagon receptor\/glucagon\u2010like peptide\u20101 receptor dual agonist that has shown promise for treating obesity and its complications in Phase 2 trials. Two double\u2010blind, randomized, global Phase 3 trials are designed to assess the efficacy and safety of survodutide for treatment of obesity\u2014SYNCHRONIZE\u2122\u20101 in people with obesity without type 2 diabetes (T2D) and SYNCHRONIZE\u2122\u20102 in people with obesity and T2D. This paper describes the baseline characteristics of participants in SYNCHRONIZE\u20102 (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      identifier NCT06066528).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>\n                      Participants aged \u226518\u2009years with a body mass index (BMI) \u226527\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      and T2D were randomized 1:1:1 to weekly subcutaneous survodutide (up\u2010titrated to 3.6 or 6.0\u2009mg) or placebo with recommendations for modified diet and physical activity. The primary endpoints are the percentage change in body weight (BW) and achievement of BW reduction of \u22655% from baseline to Week 76.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      SYNCHRONIZE\u20102 includes 752 treated participants from 133 sites across 19 countries. At baseline, participants had a mean age of 55.7\u2009years, BMI 36.5\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , BW 104.1\u2009kg, waist circumference 115.5\u2009cm and haemoglobin A1c 7.4%; 50.7% were female. Overall, 36.2% are from Europe, 32.8% from North America and 22.3% from East Asia. The most common obesity complications included hypertension (69.0%), dyslipidaemia (67.6%), obstructive sleep apnoea (17.3%) and arteriosclerotic cardiovascular disease (10.9%); 78.7% were treated with metformin, 34.2% with sodium\u2010glucose co\u2010transporter\u20102 inhibitors and 58.6% with lipid\u2010lowering medications.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SYNCHRONIZE\u20102 will determine the efficacy, safety and tolerability of survodutide for BW reduction in people with obesity and T2D, whose baseline characteristics suggest a representative, diverse cohort.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.70263","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T10:27:16Z","timestamp":1762856836000},"page":"1490-1498","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Baseline characteristics in the\n                    <scp>SYNCHRONIZE<\/scp>\n                    \u2122\u20102 randomized phase 3 trial of survodutide, a glucagon receptor\/\n                    <scp>GLP<\/scp>\n                    \u20101 receptor dual agonist, for obesity in people with type 2 diabetes"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0111-1530","authenticated-orcid":false,"given":"Sean","family":"Wharton","sequence":"first","affiliation":[{"name":"McMaster University  Hamilton Ontario Canada"},{"name":"University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5521-5445","authenticated-orcid":false,"given":"Carel W.","family":"le Roux","sequence":"additional","affiliation":[{"name":"University College Dublin School of Medicine  Dublin Ireland"},{"name":"Ulster University  Coleraine UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6362-0253","authenticated-orcid":false,"given":"Biykem","family":"Bozkurt","sequence":"additional","affiliation":[{"name":"Winters Center for Heart Failure Research, Cardiovascular Research Institute Baylor College of Medicine  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8604-0710","authenticated-orcid":false,"given":"Elke","family":"Platz","sequence":"additional","affiliation":[{"name":"Cardiovascular Division Brigham and Women's Hospital and Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4341-9042","authenticated-orcid":false,"given":"Gabriele","family":"Bleckert","sequence":"additional","affiliation":[{"name":"Staburo GmbH, Munich, Germany, on behalf of Boehringer Ingelheim Pharma GmbH &amp; Co. KG  Biberach an der Ri\u00df Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4849-0363","authenticated-orcid":false,"given":"Samina","family":"Ajaz Hussain","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH  Ingelheim am Rhein Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1215-0746","authenticated-orcid":false,"given":"Martina","family":"Brueckmann","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH  Ingelheim am Rhein Germany"},{"name":"First Department of Medicine, Faculty of Medicine Mannheim University of Heidelberg  Mannheim Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Startseva","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH  Ingelheim am Rhein Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel M.","family":"Kloer","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH  Ingelheim am Rhein Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6301-2696","authenticated-orcid":false,"given":"Lee M.","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Department of Medicine Geisel School of Medicine at Dartmouth  Hanover New Hampshire USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"issue":"45","key":"e_1_2_10_2_1","first-page":"1066","article-title":"Prevalence of overweight and obesity among adults with diagnosed diabetes\u2010\u2010United States, 1988\u20131994 and 1999\u20132002","volume":"53","author":"Centers for Disease Control and Prevention (CDC)","year":"2004","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S51325"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc25\u2010S008"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP161365.GL"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.11.004"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1159\/000442721"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(21)00213\u20100"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(23)01200\u2010X"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2025.01.021"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.2337\/dbi24\u20100026"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1113\/JP287407"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2025.171393"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2022.101633"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125\u2010023\u201006053\u20109"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213\u20108587(23)00356\u2010X"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2024.09.004"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.24184"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401755"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14948"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010145"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.24299"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2023.100076"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125\u2010022\u201005787\u20102"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl\u20102023\u2010330110"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.03.006"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2025.101320"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933\u2010018\u20100728\u20106"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300\u2010022\u201001243\u2010x"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.76"},{"issue":"1","key":"e_1_2_10_33_1","first-page":"S516","article-title":"Mazdutide vs dulaglutide in patients with type 2 diabetes (DREAMS\u20102): a randomised, open\u2010label, 28\u2010week phase 3 trial","volume":"67","author":"Guo L","year":"2024","journal-title":"Diabetologia"},{"issue":"3","key":"e_1_2_10_34_1","first-page":"245","article-title":"Effect of body mass index on all\u2010cause mortality and incidence of cardiovascular diseases\u2010\u2010report for meta\u2010analysis of prospective studies open optimal cut\u2010off points of body mass index in Chinese adults","volume":"15","author":"Zhou BF","year":"2002","journal-title":"Biomed Environ Sci"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2411528"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.70263","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/full-xml\/10.1111\/dom.70263","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.70263","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T20:48:50Z","timestamp":1769719730000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.70263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1111\/dom.70263"],"URL":"https:\/\/doi.org\/10.1111\/dom.70263","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.70263\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70263\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70263\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70263\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70263\/v2\/response1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"2025-09-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}